



## Evofem to Participate in the Virtual Investor Ask the CEO Conference

-- Live moderated video webcast with members of Evofem management team on Tuesday, October 24th at 10:00 AM ET --

SAN DIEGO, Oct. 13, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) (the "Company") today announced that **Sandra Pelletier**, Chief Executive Officer and **Amy Raskopf**, Senior Vice President, Investor Relations of Evofem will participate in the **Virtual Investor Ask the CEO Conference** on Tuesday, October 24, 2023 at 10:00 AM ET.

The "Ask the CEO" conference is intended to provide the investment community with access to ask their questions directly to management. Investors and interested parties will have the opportunity to submit questions live during the event. Questions may also be pre-submitted leading up to the event through [virtualinvestorco.com/asktheceo-evfm](https://virtualinvestorco.com/asktheceo-evfm). Participating companies will answer as many questions as possible during the event.

A **live video webcast** of the event will be available on the **Events and Presentations** page of the Company's website ([evofem.com](https://evofem.com)). A replay of the webcast will be available two hours following the live presentation and will be accessible for 90 days.

### About Evofem Biosciences, Inc.

Evofem Biosciences, Inc., is focused on commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at [phexxi.com](https://phexxi.com) and [evofem.com](https://evofem.com).

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

## Investor Contact

Amy Raskopf

SVP, Investor Relations

Evofem Biosciences, Inc.

[araskopf@evofem.com](mailto:araskopf@evofem.com)

(917) 673-5775

SOURCE Evofem Biosciences, Inc.